EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

The Lancet Oncology

ISSN 1470-2045 · Elsevier BV

Neueste Artikel

  1. Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial

    Jiajia Li, Kan Yonemori, Kaoru Niimi, Satoshi Nakagawa, Kosuke Yoshihara, Shogo Shigeta, Jianqing Zhu, Hui Qiu, Jie Tang, Hidemichi Watari, Tatsuyuki Chiyoda, Shoji Nagao, Zhiqing Liang, Yuanguang Meng, Huimei Zhou, Ruifang An, Aikou Okamoto, Shin Nishio, Kazuhiro Takehara, Junzo Hamanishi, Shuzhong Yao, Fengxia Xue, Ge Lou, Hongming Pan, Wenjun Cheng, Rutie Yin, Wei Duan, Muneaki Shimada, Yixiang Zhang, Yibin Wang, Fugen Li, Juan Chen, Chenxian Dai, Chao Lv, Jihong Liu, Xiaohua Wu

    Erschienen: 2026-11DOI: 10.1016/s1470-2045(26)00337-2

  2. Survival in patients with renal cell carcinoma and brain metastases: an update of the Renal Graded Prognostic Assessment

    Paul W Sperduto, Fasila Johri, Hany Soliman, Evan D Buckley, Kathryn E Marqueen, Enoch Chang, Jing Li, Amandeep Mahal, Rifaquat Rahman, Molly Blau, Jonathan Yang, Luke DelBalzo, Luke R G Pike, Kelsey M Frechette, William G Breen, Nuzha Noorah, G Laura Masucci, Hebah Abudawaba, Uwajachukwumma A Uzomah, John M Buatti, Eugene J Vaios, John P Kirkpatrick, Erik P Sulman, Josiah Nieto, Michelle M Kim, Mia Salans, Steve Braunstein, Sanjay Aneja, Veronica Chiang, Michael K Melton, Drexell H Boggs, Tyler Walburn, Helen A Shih, Julie Xiao, Tugce Kutuk, Rupesh Kotecha, Salah Dajani, Sean Sachdev, Geoffrey Sedor, Tony J C Wang

    Erschienen: 2026-11DOI: 10.1016/s1470-2045(26)00385-2

  3. Cancer in the Commonwealth: a Lancet Oncology Commission

    Rifat Atun, Bhawna Sirohi, David Jaffray, Ajay Aggarwal, Ros S Ahmad Bustamam, Claudia Allemani, Lawrencia Bawuah Dsane, Gabriela Borin, Karen Canfell, M Asif Chaudry, Anna J Dare, Anbang Du, Beverley M Essue, John T Figi, Aruni Ghose, Meredith Giuliani, Jason Gurney, Michael G Head, Andre Ilbawi, Jonathan C Irish, Christopher G C A Jackson, Kristina Jenei, Sonali E Johnson, Felicia Marie Knaul, Mark Lodge, Miriam Mutebi, Christian Ntizimira, Dennis A Ostwald, C S Pramesh, Che L Reddy, Lorna A Renner, Danielle Rodin, Maike Schmitt, Zainab Shinkafi-Bagudu, Isabelle Soerjomataram, Dingle Spence, Susannah Stanway, Dorit T Stein, Sugeeta Sukumar, Zuzanna Tittenbrun

    Erschienen: 2026-11DOI: 10.1016/s1470-2045(26)00396-7

  4. Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial

    Marloes J Hassing, Nicole E Billingy, Corina J G van den Hurk, Michel M van den Heuvel, Cornelia A Verberkt, Annemarie Becker-Commissaris, Iris Walraven, Hans J M Smit, Jeske A Staal van den Brekel, Frederieke Koppe, Judith Herder, Alle Welling, Olga C J Schuurbiers, Suzy M Samii, Wai Yee Lam-Wong, Wouter K de Jong, Katrien E A de Jaeger, Jos A Stigt, Nico C van Walree, Harm Jan Bogaard, Vashti N M F Tromp, Jacqueline G Hugtenburg, Bregje D Onwuteaka-Philipsen, José Belderbos, Lonneke van de Poll-Franse, Annemarie Becker-Commissaris, Iris Walraven

    Erschienen: 2026-10DOI: 10.1016/s1470-2045(26)00305-0

  5. Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus

    Jean-Michel Hannoun-Levi, Julie A Margenthaler, Bethany Anderson, Rosa Di Micco, Douglas W Arthur, Marianne Aznar, Erin E Burke, Jana de Boniface, Jill R Dietz, David Dodwell, Irma Fredriksson, Oreste D Gentilini, Benjamin Guix, Cristina Gutierrez, Ashutosh Kothari, Janice A Lyons, Icro Meattini, Angel Montero-Luis, Firas Mourtada, Toan T Nguyen, Csaba Polgar, Philip Poortmans, Nicola Rocco, Helena Sackey, Terry Sarantou, Shayna L Showalter, Vratislav Strnad, Thorsten Kuehn, Jose Volders, Marie-Jeanne Vrancken-Peeters, Catheryn Yashar, Isabel T Rubio, Jessica Gahm, Youssef Zeidan, Orit Kaidar-Person, Frederick M Dirbas

    Erschienen: 2026-09DOI: 10.1016/s1470-2045(26)00177-4

  6. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

    Masatoshi Kudo, Ghassan K Abou-Alfa, Zhenggang Ren, Jeong Heo, Riccardo Lencioni, Yasuaki Arai, Mohamed Bouattour, Maria A Gonzalez-Carmona, Yabing Guo, Ai-Bing Xu, Gustavo Vasconcelos Alves, Arunee Dechaphunkul, Gwo Fuang Ho, Yueh Ni Lim, HongTao Hu, Ruibao Liu, Shanzhi Gu, Vikas Ostwal, Witsarut Manasirisuk, Chang-Fang Chiu, Sri Harsha Tekumalla, Manish Shroff, Vimal Dave, Osama Rahma, Joseph P Erinjeri, Jia Fan, Ghassan Abou-Alfa, Mirelis Acosta-Rivera, Vivek Agarwala, Mehmet Akce, Ali Aljubran, Manon Allaire, Gustavo Alves, Lorenzo Antonuzzo, Luis Antunes, Takeshi Aramaki, Eric Assenat, Rony Avritscher, Glaucio Bertollo, Dominick Bosse

    Erschienen: 2026-09DOI: 10.1016/s1470-2045(26)00278-0

  7. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

    Xiuning Le, Antonio Passaro, Yuanyuan Zhao, Yan Huang, Janessa Laskin, Delvys Rodriguez-Abreu, Antonio Calles, Lyudmila Bazhenova, Giuseppe Lo Russo, Natasha B Leighl, Federico Cappuzzo, Nicolas Girard, Sanjay Popat, Wenfeng Fang, Yongzhong Luo, Wenting Li, Zhiyong He, Hui Zhao, Mingjun Li, Qibin Song, Hongyun Zhao, Haidar El Darsa, Isabelle Monnet, Manuel Cobo Dols, Rosario García Campelo, Robert Jotte, David Berz, Alexander Spira, Maurice Pérol, Misako Nagasaka, Howard West, Lori Styles, Jianling Li, Fong Clow, Jonathan Goldman, Li Zhang

    Erschienen: 2026-09DOI: 10.1016/s1470-2045(26)00282-2

Jahrgänge

2026 · 3642025 · 5022024 · 5012023 · 4282022 · 5502021 · 5202020 · 5272019 · 5942018 · 6362017 · 6622016 · 6602015 · 6622014 · 6212013 · 5782012 · 5822011 · 3282010 · 3302009 · 3052008 · 3332007 · 4112006 · 4422005 · 4152004 · 3212003 · 3242002 · 3462001 · 3722000 · 150

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.